Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SELLAS Life Sciences Group Inc
SLS | US
8.33
USD-0.74
-8.16%
SLS | US
About SELLAS Life Sciences Group Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
8.33
Open
8.99
High
9.00
Low
8.23
SELLAS Life Sciences Group Inc. a late-stage clinical biopharmaceutical company focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS) a cancer immunotherapeutic agent that targets Wilms tumor 1 which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co. Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai) Inc. for the development and commercialization of GFH009 a highly selective small molecule CDK9 inhibitor currently under Phase 1 clinical trials. The company is headquartered in New York New York.
View LessSLS | US
Risk
139.3
Sharpe
4.01
Luna's Score
49/100
Recommendation
Hold
Luna says (SLS | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
144.8%1 month
139.3%3 months
115.3%6 months
113.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
27.83
Debt to equity
0.24
Debt to assets
0.05
Ent. to EBITDA
-1.71
Ent. to rev.
20.84
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
535.89M
MarketCap(USD)
535.89M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-82.50
Ret. on equity
-888.06
Short ratio
17.25
Short perc.
12.74
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.66
Range1M
4.68
Range3M
5.56
Volumes: Market Activity
Rel. volume
0.93
Price X volume
84.58M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.71 | - | Cheaper |
| Ent. to Revenue | 20.84 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 27.83 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 115.28 | - | Riskier |
| Debt to Equity | 0.24 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 535.89M | - | Emerging |
